<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892292</url>
  </required_header>
  <id_info>
    <org_study_id>NGS-HLA</org_study_id>
    <nct_id>NCT02892292</nct_id>
  </id_info>
  <brief_title>NGS for HLA Typing of Donors and r√©cipients oh Hematopoietic Stem Cells</brief_title>
  <acronym>NGS HLA</acronym>
  <official_title>Next Generation Sequencing (NGS) Application for HLA Typing of Donors and Recipients of Hematopoietic Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to realize the typing of all HLA loci and validate this&#xD;
      technique with continued optimization of next-generation sequencing technology (NGS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of patients waiting allograft of hematopoietic stem cells is constantly evolving.&#xD;
      Similarly, the number of voluntary donors of hematopoietic stem cells on all global file has&#xD;
      exceeded the threshold of 22 million donors since the end of 2013. Despite this, the search&#xD;
      for a matched unrelated donor HLA for a patient remains sometimes a long and difficult,&#xD;
      especially for patients with rare HLA alleles. It is important to increase the number of&#xD;
      donors in the global file, increase HLA diversity of registrants and resolution HLA typing.&#xD;
      More HLA typing of a donor registered on the file will be accurate, more research and the&#xD;
      recruitment of a donor in order to achieve an allograft in a patient waiting will be fast.&#xD;
&#xD;
      The constant evolution of the number of HLA alleles and the number of ambiguities quickly&#xD;
      demonstrates the limits of current typing techniques. The study of exons and introns that&#xD;
      would significantly refine the level of resolution HLA typing, reaching a level of allelic&#xD;
      resolution. That level of resolution would also identify all null alleles (alleles from which&#xD;
      the protein is not expressed). The search for an HLA with a patient will be made easier by&#xD;
      reducing the financial impact and time of the search. In addition, numerous studies have&#xD;
      shown that tissue compatibility narrowest possible between the donor and recipient of an&#xD;
      allogeneic haematopoietic stem cells can improve patient survival by reducing the incidence&#xD;
      and severity of disease graft against the host and to improve engraftment.&#xD;
&#xD;
      In addition, analysis capability of the many sample using this technique should induce the&#xD;
      decrease in HLA typing costs and thus facilitate the registration of anonymous bone marrow&#xD;
      donors on the national register of the Biomedicine Agency .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HLA high resolution sequencing for loci HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 and HLA-DPB1.</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">300</enrollment>
  <condition>Next Generation Sequencing for HLA Typing</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Bone marrow donors-recipients of Brest University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bone marrow donors from Brest University Hospital&#xD;
&#xD;
          -  Bone marrow recipients of Brest University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No bone marrow donors from Brest University Hospital&#xD;
&#xD;
          -  No bone marrow recipients of Brest University Hospital&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginie Moalic-Allain, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

